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Abstract: The aim of this research was the identification of novel pharmacogenomic biomarkers
for better understanding the complex gene regulation mechanisms underpinning glucocorticoid
(GC) action in paediatric inflammatory bowel disease (IBD). This goal was achieved by evaluating
high-throughput microRNA (miRNA) profiles during GC treatment, integrated with the assessment of
expression changes in GC receptor (GR) heterocomplex genes. Furthermore, we tested the hypothesis
that differentially expressed miRNAs could be directly regulated by GCs through investigating the
presence of GC responsive elements (GREs) in their gene promoters. Ten IBD paediatric patients
responding to GCs were enrolled. Peripheral blood was obtained at diagnosis (T0) and after four
weeks of steroid treatment (T4). MicroRNA profiles were analyzed using next generation sequencing,
and selected significantly differentially expressed miRNAs were validated by quantitative reverse
transcription-polymerase chain reaction. In detail, 18 miRNAs were differentially expressed from T0
to T4, 16 of which were upregulated and 2 of which were downregulated. Out of these, three miRNAs
(miR-144, miR-142, and miR-96) could putatively recognize the 3’UTR of the GR gene and three
miRNAs (miR-363, miR-96, miR-142) contained GREs sequences, thereby potentially enabling direct
regulation by the GR. In conclusion, we identified miRNAs differently expressed during GC treatment
and miRNAs which could be directly regulated by GCs in blood cells of young IBD patients.
These results could represent a first step towards their translation as pharmacogenomic biomarkers.
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1. Introduction
Paediatric onset inflammatory bowel disease (IBD) is generally more extended, more severe,
and progresses more rapidly than the form occurring in adulthood. In spite of the introduction
of highly effective biological agents in the therapy of this disease, glucocorticoids (GCs) are still
employed to induce remission in moderate to severe forms, especially in ulcerative colitis. Nevertheless,
considerable inter-individual differences in efficacy and side effects have been reported. Although
several studies have increased the knowledge about the mechanism of action of GCs over the past
few years [1], research on the personalization of GC therapy by pharmacogenetics in IBD has only
achieved modest success to date. A potential genetic marker is the glucocorticoid receptor gene
(NR3C1), located in chromosome 5: after GC binding, the glucocorticoid receptor (GR) translocates
into the nucleus and binds palindromic DNA-binding sites, the so-called glucocorticoid responsive
elements (GREs), localized in the promoter region of target genes [2–4]. Upon DNA binding, GCs can
induce trans-activation and trans-repression processes, thus controlling gene expression. GR activity is
conditioned by the chaperone proteins heat shock protein 70 and 90, and by a number of co-chaperones,
including STIP1 and the immunophilins FKBP4 and FKBP5, which altogether form a molecular
heterocomplex with GR itself, that is required for proper ligand binding, receptor activation, and
transcription [2]. Abnormalities in proteins involved in the formation of the heterocomplex may
contribute to altered GC responsiveness [3]. Although several studies have demonstrated that
components of the heterocomplex show altered gene expression profiles in the comparison between
steroid resistant and responder patients, it is still unclear whether these changes are caused by the
variability in individual response or are the consequence of GC treatment [4–6].
These observations pinpoint the need to carry out further studies aimed to investigate the complex
gene regulatory network mediated by GCs. Within this context, non-coding microRNAs (miRNAs)
have emerged as important gene expression regulatory elements.
MicroRNAs are small (18–24 nucleotides) non-coding RNAs, which bind the 3′UTRs of their
target genes and inhibit their expression [7], either by mediating messenger RNA (mRNA) cleavage
(most common in plants) or by translational repression (most common in metazoans) [8,9]. A single
miRNA can regulate approximately 200 mRNAs, and each mRNA can in turn be regulated by multiple
miRNAs [7]. Emerging data have implicated the deregulated expression of certain miRNA networks
in the pathogenesis of autoimmune and inflammatory diseases, including IBD, and they have been
suggested to play an important role in these diseases [8–12].
In spite of the growing interest in identifying the role of miRNAs as modulators of genes involved
in drug response, the number of studies on this topic is still very limited, to the point that no data
is presently available about miRNA regulation by GCs in IBD, particularly in children. The aim of
this study was to obtain high-throughput miRNA profiles in paediatric IBD patients at diagnosis and
after the first cycle of GC therapy, used to induce remission, in order to identify miRNAs significantly
deregulated by steroid treatment. In parallel, using a candidate gene approach aimed at evaluating
selected genes involved in the molecular mechanism of response to GC treatment, we assessed the
expression changes of GR (gene name NR3C1), heterocomplex genes (FKBP4, FKBP5, and STIP1), and
GILZ (gene name TSC22D3, upregulated by GCs). The integration of these results might provide
important information about how miRNAs regulate the selected genes involved in the mechanism of
action of GCs. Finally, we investigated whether GCs could directly regulate miRNAs containing GRE
sequences in their gene promoter regions.
2. Results
2.1. miRNA Analysis
Ten paediatric IBD patients were enrolled at diagnosis at the Paediatric Clinic of IRCCS Burlo
Garofolo in Trieste in a prospective study. These patients (mean age at enrolment 12.6 years,
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range 6.2–17.8 years; 8 ulcerative colitis and 2 Crohn’s disease; 5 males and 5 females) were treated
with prednisone 1 to 2 mg/kg/day for 4 weeks.
Using the procedure described in Materials and Methods, we were able to align on a mirBase
miRNA dataset an average of 4 million reads for each sample (project accession number PRJNA297769).
The differential expression analysis identified 18 miRNAs that were differentially expressed from T0
to T4 and potentially regulated by GCs (Figure 1). In detail, a total of 16 miRNAs were upregulated
and 2 downregulated. The absolute fold changes ranged from 2.21 to 4.44 for up-regulated miRNAs,
and from −4.62 to −2.27 for the downregulated ones. Table 1 reports the list of GC-sensitive miRNAs;
those previously linked in the literature with GC regulation or whose target genes are known to be
under GC control are indicated.
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Table 1. Differentially expressed miRNAs.
Upregulated miRNAs FC FDRCorrected P-Value Downregulated miRNAs FC
FDR
Corrected p-Value
hsa-miR-451a * [13]
hsa-miR-144-3p * [14,15]
hsa-miR-96-5p * [13,14]
hsa-miR 29b-3p * [13]
hsa-miR-142-3p * [14]
hsa-miR-873-5p
hsa-miR 9c-3p * [16, 7]
hsa-miR-29a-3p * [13]
hsa-miR-363-3p
hsa-miR 141-3p
hsa-miR-548ak
hsa-let-7g-3p* [18]
hsa-miR-4772-5p
hsa-miR-106a-3p
hsa-miR-31-3p
hsa-miR-146b-5 * [19]
4.16
4.44
2.96
2.89
2.21
3.36
3.37
2.72
2.31
2.59
3.11
2.44
2. 0
3.52
3.36
2.27
1.66 × 10−6
1.04 × 10−5
6.38 × 10−3
0.026
0.026
0.026
0.037
0.041
0.041
0.041
0.042
0.042
0.047
0.047
0.049
0.049
hsa-miR-7109-3p
hsa-miR-654-5p
−4.62
−2.27
0.044
0.049
Fold changes (FC) for each miRNA regulated by glucocorticoids (GCs); * Linked to GC regulation in the literature.
FDR, False Discovery Rate.
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Three up-regulated miRNAs (i.e., miR-451a, miR-144-3p, and miR-29c-3p) were selected to
validate these results based on the magnitude of regulation and previous knowledge associating these
miRNAs to GC effects. A good agreement was observed between miRNA-seq and qRT-PCR validation
results (Figure 2).
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Figure 2. Relative expre sion of miR-451a, miR-144-3p, and miR-29c-3p (calculated as 2−∆∆Ct T4 vs.
T0). Values > 1 ( otted line) indicat upregulation, values < 1 indicate downregulation. Parametric
t-test ∆Ct 0 vs. T4, ** p < 0.01.
Three out of the 18 GC-regulated miRNA genes contained positive GC responsive element
sequences (pGREs) in their promoter regions, which represents the site potentially responsible for a
direct regulation by the GC receptor (Table 2). In detail, all three miRNA genes (i.e., miR-363, miR-96,
and miR-142) were upregulated.
Table 2. Glucocorticoid responsive element (GRE) sites predicted on miRNA promoter regions.
miRNA pGRE Start End Strand Chrom Expression
hsa-miR-363 GTGATAATGTGTGCTT 133303695 133303710 − chrX Up
hsa-miR-96 AGGACAAAGAGTCCTC 129416083 129416098 − chr7 Up
hsa-miR-142 CTCACCTTCAGTTCTG 58331606 58331621 + Chr17 Up
hsa-miR-142 CTGT TCTGTC TC 58332656 58332671 − Chr17 Up
GC- ensitive miRNAs presenti ositive GREs (pGRE).
2.2. mRNA Analysis
Candidate gene expression evaluations were performed using Taqman gene expression assays:
the regulation from T0 to T4 of GR heterocomplex genes (NR3C1, FKBP4, FKBP5, and STIP1) and GILZ,
a gene upregulated by GCs, were evaluated.
The expression of these genes did not significantly change after GC treatment (GILZ p = 0.99, CI
−1.351 to 1.361, mean RE = 2.10 ± 2.94; FKBP4 p = 0.28, CI −1.862 to 0.614, mean RE = 1.15 ± 1.16;
FKBP5 p = 0.86, CI −1.781 to 1.515, mean RE = 2.12 ± 2.39; STIP1 p = 0.44, CI −1.989 to 0.937, mean
RE = 1.62 ± 2.35). Only for NR3C1 was a trend of reduction observed (p = 0.07, CI −1.943 to 0.111,
median RE = 0.77 ± 0.62; Figure 3).
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as well as in response to Adreno Cortico Tropic Hormone (ACTH) stimulation. The authors found
that, when miR-96 or miR-142-3p were cotransfected with a vector carrying the 3′UTR region of
the NR3C1 gene into HEK293T cells, the expression of 3′UTR was significantly down-regulated,
as predicted in silico. The increased expression of these three miRNAs observed in our study after GC
treatment could be responsible for the decreased expression of NR3C1 observed at T4 in our patients.
Further studies should evaluate by flow cytometry whether the level of expression of GR in peripheral
blood mononuclear cells (PBMCs) decreases after treatment.
FKBP5, a member of the GR heterocomplex, was upregulated after GC treatment in our patients
(mean Fold Changes: 2.12 ± 2.39). This gene contains GREs which can be directly bound by GR [24].
Moreover, GR sensitivity is additionally regulated by GCs through the induction of FKBP5 expression,
thereby establishing an intracellular ultra-short negative feedback loop [25], which might sustain the
upregulation that was observed in our analysis.
Expression of miRNAs is controlled by the same mechanisms of protein coding genes, including
upstream regulatory elements (i.e., promoters). In this context, one of the most important findings
of our research was the characterization of the presence of GREs in the promoter of some of the
GC-sensitive miRNA genes identified. The consensus pGRE is composed of two hexamer half sites
separated by three random nucleotides. A majority of GREs contain the hexamer half-site sequence
TGTTCT. The number and position of GREs within gene promoter regions influences the intensity of
the transcriptional response [26].
A total of three miRNAs upregulated by GCs contained GREs. Consistently with their expression
trends, these miRNA genes presented pGREs. We can hypothesize that GCs transcriptionally regulate
the expression of some miRNAs through a GC receptor-mediated direct DNA-binding mechanism. To
the best of our knowledge, GRE motif analysis has never been carried out on miRNAs regulated by
GCs in our study. The only exception is represented by a single paper by Kong and colleagues [27],
which identified a GRE sequence in the promoter of the miR-27b gene, found to be upregulated by
dexamethasone. Out of the three miRNA genes containing GREs, miR-96 and miR-142 have been
previously related to regulation by GCs.
In particular, miR-96 modulates the transcription factor FoxO1/3, involved in GC-induced
apoptosis [13], and as discussed above, both miR-96 and miR-142 could play a role in the regulation of
GR expression [14].
Additional experiments will be required to address the significance of these findings, the binding
characteristics of the identified miRNAs, and their functional activity after exposure to GCs. Moreover,
it would be interesting to compare differential miRNA expression in cases where remission is induced
by a different therapy, to control for confounding effects independent from GCs.
In conclusion, the expression of 18 miRNAs was modulated after GC treatment in IBD paediatric
patients. Three of these miRNAs presented GREs, suggesting that GCs may possibly transcriptionally
regulate their expressions through a GC receptor-mediated direct DNA-binding mechanism. Moreover,
the changes observed in the expression of the GR gene, occurring during GC therapy, could be to some
extent linked to the regulation of miRNA by GCs. Although these results need to be confirmed and
validated in vitro, they provide new information on the possible molecular mechanism of action of
GCs and the consequent transcriptional regulation.
This study evaluated differently expressed miRNAs during GC treatment in blood cells (PBMC)
of young IBD patients enrolled at diagnosis and followed for the first four weeks of steroid therapy.
Even though a mixed cells analysis is suboptimal, since differences in gene expression can be driven by
differences in the cellular composition of starting material, the investigation of miRNA expression in
PBMCs represents a simple approach with diagnostic purpose, and easier to translate in clinical practice.
Moreover, we decided to focus our analyses on the cellular targets of GCs (PBMCs), hypothesizing a
stronger effect of GC treatment on miRNA expression in this tissue, compared to that observable in
whole blood, plasma or serum, which may be easier to collect, but may also provide expression profiles
somewhat confounded by miRNAs originating from tissues not directly involved in GC effects.
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While the number of patients studied is small, this project design, which includes patients
evaluated at diagnosis and drug naïve, can reduce to the minimum the effect of confounding factors,
and should therefore support findings with greater statistical confidence. This report may represent a
first important step towards further studies on relevant candidate GC-sensitive miRNAs.
Future investigations should be addressed at confirming these results in a larger number of
paediatric patients affected by IBD, and divided on the basis of their clinical response to GCs. In detail,
differences in the expression of miRNAs and mRNAs eventually observed at diagnosis between GC
responders and non-responders, as well as variations upon GC treatment, should be investigated
to obtain pharmacogenomic biomarkers useful to predict GC response in paediatric IBD patients.
Furthermore, the identification of pharmacological and molecular determinants associated with GC
response in paediatric IBD patients may potentially improve their treatment. Personalization of
therapy based on this information will result in higher quality of life, lower toxicity, and a more
rational treatment.
4. Materials and Methods
4.1. Patients
Ten paediatric IBD patients were enrolled at diagnosis at the Paediatric Clinic of IRCCS Burlo
Garofolo in Trieste in a prospective study. These patients (mean age at enrolment 12.6 years, range
6.2–17.8 years; 8 ulcerative colitis and 2 Crohn’s disease; 5 males and 5 females) were treated with
prednisone 1 to 2 mg/kg/day for 4 weeks. Peripheral blood was collected from enrolled patients at
diagnosis (T0) and after 4 weeks of prednisone treatment (T4). Clinical activity, inclusive of clinical
and inflammatory markers evaluation, was assessed using the “Pediatric Crohn’s Disease Activity
Index” (PCDAI) for patients with Crohn’s Disease, and with the “Pediatric Ulcerative Colitis Activity
Index” (PUCAI) for patients with ulcerative colitis. Clinical remission was defined as PCDAI < 10 or
PUCAI < 10, and clinical improvement was defined as a reduction of at least 15 points from baseline
score. These evaluations were performed at the diagnosis (before treatment), and after 4 weeks of
treatment with prednisone. All patients showed an improvement of symptoms after GC therapy at
week 4 with PCDAI = 5 and PUCAI = 3.8. These patients were hence considered GC responders and
evaluated for genomic and bioinformatic analysis.
4.2. RNA Extraction
The PBMCs of patients were collected by density gradient centrifugation on Ficoll PaqueTM
Plus (Healthcare, Milan, Italy) at diagnosis and after 30 days of therapy. The PBMCs were preserved
in RNAlater (Thermo Scientific, Waltham, MA, USA) at −80 ◦C up to the extraction, which was
done with PureLink RNA Mini kit (Thermo Scientific, Waltham, MA, USA), according to the
manufacturer’s protocol.
The RNA concentration and purity were calculated by Nano Drop instrument (NanoDrop 2000,
Thermo Scientific, Waltham, MA, USA). The amount and quality of small RNAs in the total RNA
sample was first determined with both the Agilent RNA 6000 NanoKit (Agilent, Santa Clara, CA, USA)
to generate a RIN score and the Agilent Small RNA Kit to calculate the concentration of miRNAs in
the total RNA on an Agilent 2100 Bioanalyzer.
4.3. miRNA-seq
The amount of miRNA used in the following steps was targeted at 1–25 ng, maintaining the total
RNA amount to less than 1 µg in a volume of 3 µL. The libraries were prepared with the Ion Total
RNa-seq Kit (Life Technologies, Carlsbad, CA, USA), according to manufacturer’s instructions, and the
final amplified product size was about 105 bp. The sequencing reaction was performed on an Ion
Proton platform (Life Technologies, Carlsbad, CA, USA) setting 160 flows and the mean fragment size
was about 20–25 bp.
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4.4. miRNAs Identification
Ion Proton reads were pre-processed using the cutadapt software [28] to trim the adaptor sequence
(ATCACCGACTGCCCATAGAGAGGCTGAGAC) and to remove bases with a quality score lower
than 17. All the reads with a final length lower than 15 bases were removed and were not considered
for further analysis. The remaining reads were aligned against the H. sapiens miRBase hairpin database
using PASS aligner. The reads were mapped using the local alignment mode and allowing one
mismatch. MicroRNAs were quantified considering only those reads that completely covered a mature
miRNA. Moreover, reads finding multiple matches (i.e., those mapping on multiple gene loci) were
evenly distributed among matching genes.
4.5. Differential miRNA Expression Analysis
The differential miRNA expression analysis between the samples collected at diagnosis and after
4 weeks of steroid treatment was performed using the edgeR package [29]. To take into account the
different sequencing depth among the samples, the read counts were normalized using the full quantile
normalization method implemented in the EDASeq package [30]. Differentially expressed miRNAs
were identified based on a FC threshold of |2|, coupled with a False Discovery Rate-corrected p-value
lower than 0.05.
4.6. Validation of Selected Differentially Expressed miRNAs by qRT-PCR
From the list of the top differentially expressed miRNAs, three up-regulated miRNAs
(i.e., miR-451a, miR-144-3p, miR-29c-3p) were selected for their expression validation. The expression of
these miRNAs for the validation panel was measured by qRT-PCR TaqMan® analysis using the CFX96
real-time system-C1000 Thermal Cycler (Bio-Rad Laboratories, Hercules, CA, USA). First, each miRNA
was specifically reverse-transcribed to cDNA using TaqMan miRNA RT-Kit with stem-loop RT-primer
(Applied Biosystem, Foster City, CA, USA), according to the manufacturer’s protocol. Second, PCR
products were amplified from cDNA samples using the TaqMan MicroRNA Assay together with the
TaqMan® Universal PCR Master Mix (Applied Biosystem, Foster City, CA, USA). RNU48 was used as
a reference gene for internal normalization. The relative expression levels of miRNAs before (T0) and
after treatment with GCs (T4) were calculated using the comparative Ct method (2−∆∆Ct method).
4.7. TaqMan Gene Expression Analysis
Expression levels of the selected candidate genes (NR3C1, FKBP4, FKBP5, STIP1, and TSC22D3),
were evaluated by qRT-PCR TaqMan® analysis using the CFX96 real-time system-C1000 Thermal
Cycler (Bio-Rad Laboratories, Hercules, CA, USA). The reverse transcription reaction was carried
out with the High Capacity RNA-to-cDNA Kit (Applied Biosystem, Foster City, CA, USA) and the
qRT-PCR was performed in triplicate using the TaqMan® Gene Expression Assay according to the
manufacturer’s instructions. The thermal cycling conditions for TaqMan assays were as follows: 2 min
at 50 ◦C and 10 min at 95 ◦C, followed by 40 cycles at 95 ◦C for 15 s and 60 ◦C for 60 s. The expression
levels were evaluated using the comparative Ct method (2−∆∆Ct method). Ct values were corrected
based on PCR efficiencies using LinRegPCR. Results were normalized using the 18S as a housekeeping
gene and reported as Relative Expression (RE) value.
4.8. Identification of Putative mRNA Targets
The list of mRNA targets was downloaded from mirTarBase [31], which contains experimentally
validated microRNA-target interactions. Depending on the type of experiment, the evidence is
annotated as strong (Reporter assay, Western blot, and qPCR) or weak (Microarray, NGS, pSILAC).
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4.9. Identification of GC Responsive Elements (GRE)
The positive GC Responsive Elements (pGRE) were identified using FIMO (Find Individual
Motif Occurrences) [32], part of the MEME suite [33]. We used the online web tool available at
http://meme-suite.org/tools/fimo. The positional weight matrix of the GRE motif was downloaded
from TRASFAC database, release 7.0 (accession code: M00205) [34], and was searched in the 2 kb
regions upstream of each differentially expressed miRNA gene. To discriminate between true motif
and background noise, the significance threshold was set to a p value ≤ 0.0001.
The identification of the negative GREs (nGRE) was performed using the sequences proposed by
Surjit et al. [35]. The sequences were searched using a home-made Perl script to scan the promoter
regions of miRNA with the following regular expression CTCC[A,C,G,T]0,2GGAGA and its reverse
complement in case the miRNA was coded in the reverse strand.
4.10. Statistical Analysis
Statistical analyses were performed using R software (ver. 2.9.1). Differential expression between
T0 and T4 in each gene was investigated by calculating an odds ratio (OR) and 95% confidence intervals
(CI) from contingency tables, and using paired t-test. The threshold level of statistical significance was
set to ≤0.05 after Benjamini–Hochberg FDR correction.
4.11. Ethical Considerations
Local ethical committee (Comitato indipendente per la bioetica, Istituto di Ricovero e Cura a
Carattere Scientifico materno infantile Burlo Garofolo, Trieste, Italy) approval for the study (Prot 2198;
approval date: 17 September 2013) was provided. All patients participated in this study in accordance
with the principles outlined in the Declaration of Helsinki, and written informed consent was obtained
from each participating patient and/or their parents or guardians.
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